These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2043627)

  • 1. Use of 2D NMR, protein engineering, and molecular modeling to study the hapten-binding site of an antibody Fv fragment against 2-phenyloxazolone.
    McManus S; Riechmann L
    Biochemistry; 1991 Jun; 30(24):5851-7. PubMed ID: 2043627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the antigen affinity of an antibody Fv-fragment by protein design.
    Riechmann L; Weill M; Cavanagh J
    J Mol Biol; 1992 Apr; 224(4):913-8. PubMed ID: 1569579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement.
    Riechmann L; Weill M
    Biochemistry; 1993 Aug; 32(34):8848-55. PubMed ID: 8364031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uniform labeling of a recombinant antibody Fv-fragment with 15N and 13C for heteronuclear NMR spectroscopy.
    Riechmann L; Cavanagh J; McManus S
    FEBS Lett; 1991 Aug; 287(1-2):185-8. PubMed ID: 1879529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-dimensional structure determination of an anti-2-phenyloxazolone antibody: the role of somatic mutation and heavy/light chain pairing in the maturation of an immune response.
    Alzari PM; Spinelli S; Mariuzza RA; Boulot G; Poljak RJ; Jarvis JM; Milstein C
    EMBO J; 1990 Dec; 9(12):3807-14. PubMed ID: 2123450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Diabodies": small bivalent and bispecific antibody fragments.
    Holliger P; Prospero T; Winter G
    Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6444-8. PubMed ID: 8341653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-tagged antibodies: bacterial expression and characterization of a lipoprotein-single-chain antibody fusion protein.
    Laukkanen ML; Teeri TT; Keinänen K
    Protein Eng; 1993 Jun; 6(4):449-54. PubMed ID: 8332603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modelling study of antigen binding to oxazolone-specific antibodies: the Ox1 idiotypic IgG and its mature variant with increased affinity to 2-phenyloxazolone.
    Holm L; Laaksonen L; Kaartinen M; Teeri TT; Knowles JK
    Protein Eng; 1990 Apr; 3(5):403-9. PubMed ID: 2349210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Properties of a single-chain antibody containing different linker peptides.
    Alfthan K; Takkinen K; Sizmann D; Söderlund H; Teeri TT
    Protein Eng; 1995 Jul; 8(7):725-31. PubMed ID: 8577701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of FV and Fab fragments of the antibody McPC603 expressed in E. coli.
    Plückthun A; Glockshuber R; Skerra A; Stadmüller J
    Behring Inst Mitt; 1990 Dec; (87):48-55. PubMed ID: 2096820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and dynamic properties of the Fv fragment and the single-chain Fv fragment of an antibody in solution investigated by heteronuclear three-dimensional NMR spectroscopy.
    Freund C; Ross A; Plückthun A; Holak TA
    Biochemistry; 1994 Mar; 33(11):3296-303. PubMed ID: 8136365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative analysis of the immunological evolution of antibody 28B4.
    Yin J; Mundorff EC; Yang PL; Wendt KU; Hanway D; Stevens RC; Schultz PG
    Biochemistry; 2001 Sep; 40(36):10764-73. PubMed ID: 11535051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation and selection during the secondary response to 2-phenyloxazolone.
    Rada C; Gupta SK; Gherardi E; Milstein C
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5508-12. PubMed ID: 1905811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional structure of murine anti-p-azophenylarsonate Fab 36-71. 1. X-ray crystallography, site-directed mutagenesis, and modeling of the complex with hapten.
    Strong RK; Campbell R; Rose DR; Petsko GA; Sharon J; Margolies MN
    Biochemistry; 1991 Apr; 30(15):3739-48. PubMed ID: 2015229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody--hapten interactions in solution.
    Dwek RA; Jones R; Marsh D; McLaughlin AC; Press EM; Price NC; White AI
    Philos Trans R Soc Lond B Biol Sci; 1975 Nov; 272(915):53-74. PubMed ID: 1818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the conformational diversity by random insertions to CDRH2 results in improved anti-estradiol antibodies.
    Lamminmäki U; Paupério S; Westerlund-Karlsson A; Karvinen J; Virtanen PL; Lövgren T; Saviranta P
    J Mol Biol; 1999 Aug; 291(3):589-602. PubMed ID: 10448039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural implications of somatic mutations during the immune response to 2-phenyloxazolone.
    Spinelli S; Alzari PM
    Res Immunol; 1994 Jan; 145(1):41-5. PubMed ID: 7516564
    [No Abstract]   [Full Text] [Related]  

  • 18. Protein engineering of single-chain Fv analogs and fusion proteins.
    Huston JS; Mudgett-Hunter M; Tai MS; McCartney J; Warren F; Haber E; Oppermann H
    Methods Enzymol; 1991; 203():46-88. PubMed ID: 1762568
    [No Abstract]   [Full Text] [Related]  

  • 19. The de novo design of an antibody combining site. Crystallographic analysis of the VL domain confirms the structural model.
    Essen LO; Skerra A
    J Mol Biol; 1994 Apr; 238(2):226-44. PubMed ID: 8158652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation.
    Figini M; Marks JD; Winter G; Griffiths AD
    J Mol Biol; 1994 May; 239(1):68-78. PubMed ID: 8196048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.